Two oral NLRP3 inhibitors produced by Inflazome, inzomelid (clinical trials identifier: NCT04086602) and Somalix, are intended for the treatment of cryopyrin-associated periodic syndrome (CAPS) and cardiovascular disease, respectively [369]. This evidence concerns the gene NLRP3 and cryopyrin-associated periodic syndrome.